{"parse":{"title":"In silico clinical trials","pageid":46232572,"revid":841420357,"text":{"*":"<div class=\"mw-parser-output\"><p>An <b><i>in silico</i> clinical trial</b> is an individualised <a href=\"/wiki/Computer_simulation\" title=\"Computer simulation\">computer simulation</a> used in the development or regulatory evaluation of a <a href=\"/wiki/Medicinal_product\" class=\"mw-redirect\" title=\"Medicinal product\">medicinal product</a>, <a href=\"/wiki/Medical_device\" title=\"Medical device\">device</a>, or intervention. While completely simulated <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trials</a> are not feasible with current technology and understanding of biology, its development would be expected to have major benefits over current <i><a href=\"/wiki/In_vivo\" title=\"In vivo\">in vivo</a></i> clinical trials, and research on it is being pursued.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#History\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">History</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Rationale\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Rationale</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Aim\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Aim</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#See_also\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#References\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#External_links\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=In_silico_clinical_trials&amp;action=edit&amp;section=1\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The term <i>in silico</i> indicates any use of computers in clinical trials, even if limited to management of clinical information in a database.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Rationale\">Rationale</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=In_silico_clinical_trials&amp;action=edit&amp;section=2\" title=\"Edit section: Rationale\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The traditional model for the development of medical treatments and devices begins with <a href=\"/wiki/Pre-clinical_development\" title=\"Pre-clinical development\">pre-clinical development</a>. In laboratories, test-tube and other <i><a href=\"/wiki/In_vitro\" title=\"In vitro\">in vitro</a></i> experiments establish the plausibility for the efficacy of the treatment.  Then <i><a href=\"/wiki/In_vivo\" title=\"In vivo\">in vivo</a></i> <a href=\"/wiki/Animal_models\" class=\"mw-redirect\" title=\"Animal models\">animal models</a>, with different species, provide guidance on the efficacy and safety of the product for humans. With success in both <i>in vitro</i> and <i>in vivo</i> studies, scientist can propose that <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trials</a> test whether the product be made available for humans. Clinical trials are often divided into four phases. Phase 3  involves testing a large number of people.<sup id=\"cite_ref-Trial_Watch_2-0\" class=\"reference\"><a href=\"#cite_note-Trial_Watch-2\">&#91;2&#93;</a></sup> When a medication fails at this stage, the financial losses can be catastrophic.<sup id=\"cite_ref-Model-Based_Drug_Development_3-0\" class=\"reference\"><a href=\"#cite_note-Model-Based_Drug_Development-3\">&#91;3&#93;</a></sup>\n</p><p>Predicting low-frequency side effects has been difficult, because such side effects need not become apparent until the treatment is adopted by many patients. The appearance of severe side-effects in phase three often causes development to stop, for ethical and economic reasons.<sup id=\"cite_ref-Trial_Watch_2-1\" class=\"reference\"><a href=\"#cite_note-Trial_Watch-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Modeling_and_Similation_as_a_tool._Harnisch_4-0\" class=\"reference\"><a href=\"#cite_note-Modeling_and_Similation_as_a_tool._Harnisch-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-canine_cardiac_midmyocardial_model_5-0\" class=\"reference\"><a href=\"#cite_note-canine_cardiac_midmyocardial_model-5\">&#91;5&#93;</a></sup> Also, in recent years many candidate drugs failed in phase 3 trials because of lack of efficacy rather than for safety reasons.<sup id=\"cite_ref-Trial_Watch_2-2\" class=\"reference\"><a href=\"#cite_note-Trial_Watch-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Model-Based_Drug_Development_3-1\" class=\"reference\"><a href=\"#cite_note-Model-Based_Drug_Development-3\">&#91;3&#93;</a></sup> One reason for failure is that traditional trials aim to establish efficacy and safety for most subjects, rather than for individual subjects, and so efficacy is determined by a <a href=\"/wiki/Statistic\" title=\"Statistic\">statistic</a> of <a href=\"/wiki/Central_tendency\" title=\"Central tendency\">central tendency</a> for the trial. Traditional trials do not adapt the treatment to the <a href=\"/wiki/Covariate\" class=\"mw-redirect\" title=\"Covariate\">covariates</a> of subjects: \n</p>\n<ul><li>Taking account of factors such as the patient's particular physiology, the individual manifestation of the disease being treated, their lifestyle, and the presence of co-morbidities.<sup id=\"cite_ref-Modeling_and_Similation_as_a_tool._Harnisch_4-1\" class=\"reference\"><a href=\"#cite_note-Modeling_and_Similation_as_a_tool._Harnisch-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-A_Vision_and_Strategy_for_VPH._Hunter_et_al._6-0\" class=\"reference\"><a href=\"#cite_note-A_Vision_and_Strategy_for_VPH._Hunter_et_al.-6\">&#91;6&#93;</a></sup></li>\n<li><a href=\"/wiki/Compliance_(medicine)\" class=\"mw-redirect\" title=\"Compliance (medicine)\">Compliance</a>, or lack thereof, in taking the drug at the times and dose prescribed. In the case of a surgically implanted device, to account for the variability in surgeons\u2019 experience and technique, as well as the particular anatomy of the patient.<sup id=\"cite_ref-Pre-clinical_validation_of_joint_prostheses._Viceconti_7-0\" class=\"reference\"><a href=\"#cite_note-Pre-clinical_validation_of_joint_prostheses._Viceconti-7\">&#91;7&#93;</a></sup> However, adjusting the evaluation of the study for noncompliance has proved difficult. Such adjustments often bias the results of the study, and so many health authorities mandate that clinical trials analyse the data according to the <a href=\"/wiki/Intention_to_treat\" class=\"mw-redirect\" title=\"Intention to treat\">intention to treat</a> principle.</li></ul>\n<h2><span class=\"mw-headline\" id=\"Aim\">Aim</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=In_silico_clinical_trials&amp;action=edit&amp;section=3\" title=\"Edit section: Aim\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Accurate computer models of a treatment and its deployment, as well as patient characteristics, are necessary precursors for the development of <i>in silico</i> clinical trials.<sup id=\"cite_ref-canine_cardiac_midmyocardial_model_5-1\" class=\"reference\"><a href=\"#cite_note-canine_cardiac_midmyocardial_model-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-A_Vision_and_Strategy_for_VPH._Hunter_et_al._6-1\" class=\"reference\"><a href=\"#cite_note-A_Vision_and_Strategy_for_VPH._Hunter_et_al.-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman_8-0\" class=\"reference\"><a href=\"#cite_note-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-In_silico_design_of_clinical_trials.Clermont_9-0\" class=\"reference\"><a href=\"#cite_note-In_silico_design_of_clinical_trials.Clermont-9\">&#91;9&#93;</a></sup>  In such a scenario, \u2018virtual\u2019 patients would be given a \u2018virtual\u2019 treatment, enabling observation through a computer simulation of how the candidate biomedical product performs and whether it produces the intended effect, without inducing adverse effects.  Such <i>in silico</i> clinical trials could help to reduce, refine, and partially replace real clinical trials by:\n</p>\n<ul><li>Reducing the size and the duration of clinical trials through better design,<sup id=\"cite_ref-A_Vision_and_Strategy_for_VPH._Hunter_et_al._6-2\" class=\"reference\"><a href=\"#cite_note-A_Vision_and_Strategy_for_VPH._Hunter_et_al.-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman_8-1\" class=\"reference\"><a href=\"#cite_note-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman-8\">&#91;8&#93;</a></sup> for example, by identifying characteristics to determine which patients might be at greater risk of complications or providing earlier confirmation that the product is working as expected.<sup id=\"cite_ref-canine_cardiac_midmyocardial_model_5-2\" class=\"reference\"><a href=\"#cite_note-canine_cardiac_midmyocardial_model-5\">&#91;5&#93;</a></sup></li>\n<li>Refining clinical trials through clearer, more detailed information on potential outcomes and greater explanatory power in interpreting any adverse effects that might emerge, as well as better understanding of how the tested product interacts with the individual patient anatomy and predicting long-term or rare effects that clinical trials are unlikely to reveal.<sup id=\"cite_ref-In_silico_design_of_clinical_trials.Clermont_9-1\" class=\"reference\"><a href=\"#cite_note-In_silico_design_of_clinical_trials.Clermont-9\">&#91;9&#93;</a></sup></li>\n<li>Partially replacing clinical trials in those situations where it is not an absolute regulatory necessity, but only a legal requirement. There are already examples where regulators have accepted the replacement of animal models with <i>in silico</i> models under appropriate conditions.<sup id=\"cite_ref-In_silico_preclinical_trials:_a_proof_of_concept_in_closed-loop_control_of_type_1_diabetes._Kovatchev_10-0\" class=\"reference\"><a href=\"#cite_note-In_silico_preclinical_trials:_a_proof_of_concept_in_closed-loop_control_of_type_1_diabetes._Kovatchev-10\">&#91;10&#93;</a></sup> While real clinical trials will remain essential in most cases, there are specific situations where a reliable predictive model can conceivably replace a routine clinical assessment.</li></ul>\n<p>In addition, real clinical trials may indicate that a product is unsafe or ineffective, but rarely indicate why or suggest how it might be improved. As such, a product that fails during clinical trials may simply be abandoned, even if a small modification would solve the problem. This stifles innovation, decreasing the number of truly original biomedical products presented to the market every year, and at the same time increasing the cost of development.<sup id=\"cite_ref-Avicenna_Roadmap_2015_Viceconti_11-0\" class=\"reference\"><a href=\"#cite_note-Avicenna_Roadmap_2015_Viceconti-11\">&#91;11&#93;</a></sup>\nAnalysis through <i>in silico</i> clinical trials is expected to provide a better understanding of the mechanism that caused the product to fail in testing,<sup id=\"cite_ref-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman_8-2\" class=\"reference\"><a href=\"#cite_note-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-The_Role_of_Modeling_and_Simulation_in_Development_and_Registration_of_Medicinal_Products:_Output_From_the_EFPIA/EMA_Modeling_and_Simulation_Workshop._Manolis_12-0\" class=\"reference\"><a href=\"#cite_note-The_Role_of_Modeling_and_Simulation_in_Development_and_Registration_of_Medicinal_Products:_Output_From_the_EFPIA/EMA_Modeling_and_Simulation_Workshop._Manolis-12\">&#91;12&#93;</a></sup> and may be able to provide information that could be used to refine the product to such a degree that it could successfully complete clinical trials.\n</p><p><i>In silico</i> clinical trials would also provide significant benefits over current pre-clinical practices. Unlike animal models, the virtual human models can be re-used indefinitely, providing significant cost savings.  Compared to trials in animals or a small sample of humans, <i>in silico</i> trials might more effectively predict the behaviour of the drug or device in large-scale trials, identifying side effects that were previously difficult or impossible to detect, helping to prevent unsuitable candidates from progressing to the costly phase 3 trials.<sup id=\"cite_ref-Avicenna_Roadmap_2015_Viceconti_11-1\" class=\"reference\"><a href=\"#cite_note-Avicenna_Roadmap_2015_Viceconti-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=In_silico_clinical_trials&amp;action=edit&amp;section=4\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Virtual_Physiological_Human\" title=\"Virtual Physiological Human\">Virtual Physiological Human</a></li>\n<li><a href=\"/wiki/In_silico_medicine\" title=\"In silico medicine\"><i>in silico</i> medicine</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=In_silico_clinical_trials&amp;action=edit&amp;section=5\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><i><a href=\"//creativecommons.org/licenses/by/4.0/\" title=\"creativecommons:by/4.0/\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/b/b1/CC-BY-icon-80x15.png\" width=\"80\" height=\"15\" data-file-width=\"80\" data-file-height=\"15\" /></a>&#160;This article incorporates <a rel=\"nofollow\" class=\"external text\" href=\"http://avicenna-isct.org/wp-content/uploads/2015/05/Avicenna_roadmap_v3.pdf\">text</a> available under the <a href=\"//creativecommons.org/licenses/by/4.0/\" class=\"extiw\" title=\"creativecommons:by/4.0/\">CC BY 4.0</a> license.</i>\n</p>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\">This sense of the term was used in 2011 in a position paper from the VPH Institute commenting on the <a href=\"/wiki/Green_paper\" title=\"Green paper\">green paper</a> written ahead of the launch of the <a href=\"/wiki/European_Commission\" title=\"European Commission\">European Commission</a> <a href=\"/wiki/Horizon_2020\" class=\"mw-redirect\" title=\"Horizon 2020\">Horizon 2020</a> framework programme.\n\n<a rel=\"nofollow\" class=\"external text\" href=\"http://www.vph-institute.org/upload/vphinst-position-on-fp8-greenpaper-v3_5192443874603.pdf\">VPH greenpaper</a></span>\n</li>\n<li id=\"cite_note-Trial_Watch-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Trial_Watch_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Trial_Watch_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Trial_Watch_2-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Arrowsmith, John; Miller, Philip (1 August 2013). \"Trial Watch: Phase II and Phase III attrition rates 2011\u20132012\". <i>Nature Reviews Drug Discovery</i>. <b>12</b> (8): 569. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/nrd4090\">10.1038/nrd4090</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23903212\">23903212</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews+Drug+Discovery&amp;rft.atitle=Trial+Watch%3A+Phase+II+and+Phase+III+attrition+rates+2011%E2%80%932012&amp;rft.volume=12&amp;rft.issue=8&amp;rft.pages=569&amp;rft.date=2013-08-01&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd4090&amp;rft_id=info%3Apmid%2F23903212&amp;rft.aulast=Arrowsmith&amp;rft.aufirst=John&amp;rft.au=Miller%2C+Philip&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Model-Based_Drug_Development-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Model-Based_Drug_Development_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Model-Based_Drug_Development_3-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Milligan, P A; Brown, M J; Marchant, B; Martin, S W; van der Graaf, P H; Benson, N; Nucci, G; Nichols, D J; Boyd, R A; Mandema, J W; Krishnaswami, S; Zwillich, S; Gruben, D; Anziano, R J; Stock, T C; Lalonde, R L (14 March 2013). \"Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development\". <i>Clinical Pharmacology &amp; Therapeutics</i>. <b>93</b> (6): 502\u2013514. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/clpt.2013.54\">10.1038/clpt.2013.54</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Pharmacology+%26+Therapeutics&amp;rft.atitle=Model-Based+Drug+Development%3A+A+Rational+Approach+to+Efficiently+Accelerate+Drug+Development&amp;rft.volume=93&amp;rft.issue=6&amp;rft.pages=502-514&amp;rft.date=2013-03-14&amp;rft_id=info%3Adoi%2F10.1038%2Fclpt.2013.54&amp;rft.aulast=Milligan&amp;rft.aufirst=P+A&amp;rft.au=Brown%2C+M+J&amp;rft.au=Marchant%2C+B&amp;rft.au=Martin%2C+S+W&amp;rft.au=van+der+Graaf%2C+P+H&amp;rft.au=Benson%2C+N&amp;rft.au=Nucci%2C+G&amp;rft.au=Nichols%2C+D+J&amp;rft.au=Boyd%2C+R+A&amp;rft.au=Mandema%2C+J+W&amp;rft.au=Krishnaswami%2C+S&amp;rft.au=Zwillich%2C+S&amp;rft.au=Gruben%2C+D&amp;rft.au=Anziano%2C+R+J&amp;rft.au=Stock%2C+T+C&amp;rft.au=Lalonde%2C+R+L&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Modeling_and_Similation_as_a_tool._Harnisch-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Modeling_and_Similation_as_a_tool._Harnisch_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Modeling_and_Similation_as_a_tool._Harnisch_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Harnisch, L; Shepard, T; Pons, G; Della Pasqua, O (February 2013). \"Modeling and Simulation as a Tool to Bridge Efficacy and Safety Data in Special Populations\". <i>CPT: Pharmacometrics &amp; Systems Pharmacology</i>. <b>2</b> (2): e28. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/psp.2013.6\">10.1038/psp.2013.6</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CPT%3A+Pharmacometrics+%26+Systems+Pharmacology&amp;rft.atitle=Modeling+and+Simulation+as+a+Tool+to+Bridge+Efficacy+and+Safety+Data+in+Special+Populations&amp;rft.volume=2&amp;rft.issue=2&amp;rft.pages=e28&amp;rft.date=2013-02&amp;rft_id=info%3Adoi%2F10.1038%2Fpsp.2013.6&amp;rft.aulast=Harnisch&amp;rft.aufirst=L&amp;rft.au=Shepard%2C+T&amp;rft.au=Pons%2C+G&amp;rft.au=Della+Pasqua%2C+O&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-canine_cardiac_midmyocardial_model-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-canine_cardiac_midmyocardial_model_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-canine_cardiac_midmyocardial_model_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-canine_cardiac_midmyocardial_model_5-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Davies, M. R.; Mistry, H. B.; Hussein, L.; Pollard, C. E.; Valentin, J.- P.; Swinton, J.; Abi-Gerges, N. (23 December 2011). \"An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment\". <i>AJP: Heart and Circulatory Physiology</i>. <b>302</b> (7): H1466\u2013H1480. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1152/ajpheart.00808.2011\">10.1152/ajpheart.00808.2011</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AJP%3A+Heart+and+Circulatory+Physiology&amp;rft.atitle=An+in+silico+canine+cardiac+midmyocardial+action+potential+duration+model+as+a+tool+for+early+drug+safety+assessment&amp;rft.volume=302&amp;rft.issue=7&amp;rft.pages=H1466-H1480&amp;rft.date=2011-12-23&amp;rft_id=info%3Adoi%2F10.1152%2Fajpheart.00808.2011&amp;rft.aulast=Davies&amp;rft.aufirst=M.+R.&amp;rft.au=Mistry%2C+H.+B.&amp;rft.au=Hussein%2C+L.&amp;rft.au=Pollard%2C+C.+E.&amp;rft.au=Valentin%2C+J.-+P.&amp;rft.au=Swinton%2C+J.&amp;rft.au=Abi-Gerges%2C+N.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-A_Vision_and_Strategy_for_VPH._Hunter_et_al.-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-A_Vision_and_Strategy_for_VPH._Hunter_et_al._6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-A_Vision_and_Strategy_for_VPH._Hunter_et_al._6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-A_Vision_and_Strategy_for_VPH._Hunter_et_al._6-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hunter, P.; Chapman, T.; Coveney, P. V.; de Bono, B.; Diaz, V.; Fenner, J.; Frangi, A. F.; Harris, P.; Hose, R.; Kohl, P.; Lawford, P.; McCormack, K.; Mendes, M.; Omholt, S.; Quarteroni, A.; Shublaq, N.; Skar, J.; Stroetmann, K.; Tegner, J.; Thomas, S. R.; Tollis, I.; Tsamardinos, I.; van Beek, J. H. G. M.; Viceconti, M. (21 February 2013). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3638492\">\"A vision and strategy for the virtual physiological human: 2012 update\"</a>. <i>Interface Focus</i>. <b>3</b> (2): 20130004\u201320130004. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1098/rsfs.2013.0004\">10.1098/rsfs.2013.0004</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3638492\">3638492</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Interface+Focus&amp;rft.atitle=A+vision+and+strategy+for+the+virtual+physiological+human%3A+2012+update&amp;rft.volume=3&amp;rft.issue=2&amp;rft.pages=20130004-20130004&amp;rft.date=2013-02-21&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3638492&amp;rft_id=info%3Adoi%2F10.1098%2Frsfs.2013.0004&amp;rft.aulast=Hunter&amp;rft.aufirst=P.&amp;rft.au=Chapman%2C+T.&amp;rft.au=Coveney%2C+P.+V.&amp;rft.au=de+Bono%2C+B.&amp;rft.au=Diaz%2C+V.&amp;rft.au=Fenner%2C+J.&amp;rft.au=Frangi%2C+A.+F.&amp;rft.au=Harris%2C+P.&amp;rft.au=Hose%2C+R.&amp;rft.au=Kohl%2C+P.&amp;rft.au=Lawford%2C+P.&amp;rft.au=McCormack%2C+K.&amp;rft.au=Mendes%2C+M.&amp;rft.au=Omholt%2C+S.&amp;rft.au=Quarteroni%2C+A.&amp;rft.au=Shublaq%2C+N.&amp;rft.au=Skar%2C+J.&amp;rft.au=Stroetmann%2C+K.&amp;rft.au=Tegner%2C+J.&amp;rft.au=Thomas%2C+S.+R.&amp;rft.au=Tollis%2C+I.&amp;rft.au=Tsamardinos%2C+I.&amp;rft.au=van+Beek%2C+J.+H.+G.+M.&amp;rft.au=Viceconti%2C+M.&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3638492&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Pre-clinical_validation_of_joint_prostheses._Viceconti-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Pre-clinical_validation_of_joint_prostheses._Viceconti_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Viceconti, Marco; Affatato, Saverio; Baleani, Massimiliano; Bordini, Barbara; Cristofolini, Luca; Taddei, Fulvia (2009). \"Pre-clinical validation of joint prostheses: a systematic approach\". <i>Journal of the mechanical behavior of biomedical materials 2</i>: 120\u2013127.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+the+mechanical+behavior+of+biomedical+materials+2&amp;rft.atitle=Pre-clinical+validation+of+joint+prostheses%3A+a+systematic+approach.&amp;rft.pages=120-127&amp;rft.date=2009&amp;rft.aulast=Viceconti&amp;rft.aufirst=Marco&amp;rft.au=Affatato%2C+Saverio&amp;rft.au=Baleani%2C+Massimiliano&amp;rft.au=Bordini%2C+Barbara&amp;rft.au=Cristofolini%2C+Luca&amp;rft.au=Taddei%2C+Fulvia&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman_8-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Grand_Challenge:_Applying_Regulatory_Science_and_Big_Data_to_Improve_Medical_Device_Innovation._Erdman_8-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Erdman, A. G.; Keefe, D. F.; Schiestl, R. (March 2013). \"Grand Challenge: Applying Regulatory Science and Big Data to Improve Medical Device Innovation\". <i>IEEE Transactions on Biomedical Engineering</i>. <b>60</b> (3): 700\u2013706. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1109/TBME.2013.2244600\">10.1109/TBME.2013.2244600</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=IEEE+Transactions+on+Biomedical+Engineering&amp;rft.atitle=Grand+Challenge%3A+Applying+Regulatory+Science+and+Big+Data+to+Improve+Medical+Device+Innovation&amp;rft.volume=60&amp;rft.issue=3&amp;rft.pages=700-706&amp;rft.date=2013-03&amp;rft_id=info%3Adoi%2F10.1109%2FTBME.2013.2244600&amp;rft.aulast=Erdman&amp;rft.aufirst=A.+G.&amp;rft.au=Keefe%2C+D.+F.&amp;rft.au=Schiestl%2C+R.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-In_silico_design_of_clinical_trials.Clermont-9\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-In_silico_design_of_clinical_trials.Clermont_9-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-In_silico_design_of_clinical_trials.Clermont_9-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Clermont, Gilles; Bartels, John; Kumar, Rukmini; Constantine, Greg; Vodovotz, Yoram; Chow, Carson (October 2004). \"In silico design of clinical trials: A method coming of age\". <i>Critical Care Medicine</i>. <b>32</b> (10): 2061\u20132070. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/01.CCM.0000142394.28791.C3\">10.1097/01.CCM.0000142394.28791.C3</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Critical+Care+Medicine&amp;rft.atitle=In+silico+design+of+clinical+trials%3A+A+method+coming+of+age&amp;rft.volume=32&amp;rft.issue=10&amp;rft.pages=2061-2070&amp;rft.date=2004-10&amp;rft_id=info%3Adoi%2F10.1097%2F01.CCM.0000142394.28791.C3&amp;rft.aulast=Clermont&amp;rft.aufirst=Gilles&amp;rft.au=Bartels%2C+John&amp;rft.au=Kumar%2C+Rukmini&amp;rft.au=Constantine%2C+Greg&amp;rft.au=Vodovotz%2C+Yoram&amp;rft.au=Chow%2C+Carson&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-In_silico_preclinical_trials:_a_proof_of_concept_in_closed-loop_control_of_type_1_diabetes._Kovatchev-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-In_silico_preclinical_trials:_a_proof_of_concept_in_closed-loop_control_of_type_1_diabetes._Kovatchev_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kovatchev, BP; Breton, M; Man, CD; Cobelli, C (January 2009). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2681269\">\"In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes\"</a>. <i>Journal of diabetes science and technology</i>. <b>3</b> (1): 44\u201355. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/193229680900300106\">10.1177/193229680900300106</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2681269\">2681269</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19444330\">19444330</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+diabetes+science+and+technology&amp;rft.atitle=In+silico+preclinical+trials%3A+a+proof+of+concept+in+closed-loop+control+of+type+1+diabetes.&amp;rft.volume=3&amp;rft.issue=1&amp;rft.pages=44-55&amp;rft.date=2009-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2681269&amp;rft_id=info%3Apmid%2F19444330&amp;rft_id=info%3Adoi%2F10.1177%2F193229680900300106&amp;rft.aulast=Kovatchev&amp;rft.aufirst=BP&amp;rft.au=Breton%2C+M&amp;rft.au=Man%2C+CD&amp;rft.au=Cobelli%2C+C&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2681269&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Avicenna_Roadmap_2015_Viceconti-11\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Avicenna_Roadmap_2015_Viceconti_11-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Avicenna_Roadmap_2015_Viceconti_11-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite id=\"AvicennaRoadmap\" class=\"citation web\">Viceconti, Marco; Morley-Fletcher, Edwin; Henney, Adriano; Contin, Martina; El-Arifi, Karen; McGregor, Callum; Karlstrom, Anders; Wilkinson, Emma. <a rel=\"nofollow\" class=\"external text\" href=\"http://avicenna-isct.org/wp-content/uploads/2015/05/Avicenna_roadmap_v3.pdf\">\"In Silico Clinical Trials: How Computer Simulation Will Transform The Biomedical Industry An international research and development roadmap for an industry-driven initiative\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Avicenna-ISCT</i>. Avicenna Project<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">1 June</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Avicenna-ISCT&amp;rft.atitle=In+Silico+Clinical+Trials%3A+How+Computer+Simulation+Will+Transform+The+Biomedical+Industry+An+international+research+and+development+roadmap+for+an+industry-driven+initiative&amp;rft.aulast=Viceconti&amp;rft.aufirst=Marco&amp;rft.au=Morley-Fletcher%2C+Edwin&amp;rft.au=Henney%2C+Adriano&amp;rft.au=Contin%2C+Martina&amp;rft.au=El-Arifi%2C+Karen&amp;rft.au=McGregor%2C+Callum&amp;rft.au=Karlstrom%2C+Anders&amp;rft.au=Wilkinson%2C+Emma&amp;rft_id=http%3A%2F%2Favicenna-isct.org%2Fwp-content%2Fuploads%2F2015%2F05%2FAvicenna_roadmap_v3.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-The_Role_of_Modeling_and_Simulation_in_Development_and_Registration_of_Medicinal_Products:_Output_From_the_EFPIA/EMA_Modeling_and_Simulation_Workshop._Manolis-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-The_Role_of_Modeling_and_Simulation_in_Development_and_Registration_of_Medicinal_Products:_Output_From_the_EFPIA/EMA_Modeling_and_Simulation_Workshop._Manolis_12-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Manolis, E; Rohou, S; Hemmings, R; Salmonson, T; Karlsson, M; Milligan, P A (February 2013). \"The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop\". <i>CPT: Pharmacometrics &amp; Systems Pharmacology</i>. <b>2</b> (2): e31. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/psp.2013.7\">10.1038/psp.2013.7</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CPT%3A+Pharmacometrics+%26+Systems+Pharmacology&amp;rft.atitle=The+Role+of+Modeling+and+Simulation+in+Development+and+Registration+of+Medicinal+Products%3A+Output+From+the+EFPIA%2FEMA+Modeling+and+Simulation+Workshop&amp;rft.volume=2&amp;rft.issue=2&amp;rft.pages=e31&amp;rft.date=2013-02&amp;rft_id=info%3Adoi%2F10.1038%2Fpsp.2013.7&amp;rft.aulast=Manolis&amp;rft.aufirst=E&amp;rft.au=Rohou%2C+S&amp;rft.au=Hemmings%2C+R&amp;rft.au=Salmonson%2C+T&amp;rft.au=Karlsson%2C+M&amp;rft.au=Milligan%2C+P+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AIn+silico+clinical+trials\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=In_silico_clinical_trials&amp;action=edit&amp;section=6\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.taverna.org.uk/introduction/what-is-in-silico-experimentation/\">Taverna site</a> <i>What is in-silico experimentation?</i></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw1230\nCached time: 20180908153118\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.192 seconds\nReal time usage: 0.230 seconds\nPreprocessor visited node count: 933/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 27855/2097152 bytes\nTemplate argument size: 274/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 24530/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.089/10.000 seconds\nLua memory usage: 3.03 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  177.506      1 -total\n 95.77%  169.991      1 Template:Reflist\n 61.14%  108.528     10 Template:Cite_journal\n  4.53%    8.036      1 Template:Cite_web\n  4.19%    7.439      1 Template:CC-notice\n  3.03%    5.376      1 Template:Main_other\n  1.02%    1.811      1 Template:Column-width\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:46232572-0!canonical and timestamp 20180908153118 and revision id 841420357\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Articles_with_imported_freely_licensed_text"},{"sortkey":"","*":"Medical_technology"},{"sortkey":"","*":"Computational_science"},{"sortkey":"","*":"Anatomical_simulation"},{"sortkey":"","*":"Clinical_research"}],"links":[{"ns":0,"exists":"","*":"Animal models"},{"ns":0,"exists":"","*":"Central tendency"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Compliance (medicine)"},{"ns":0,"exists":"","*":"Computer simulation"},{"ns":0,"exists":"","*":"Covariate"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"European Commission"},{"ns":0,"exists":"","*":"Green paper"},{"ns":0,"exists":"","*":"Horizon 2020"},{"ns":0,"exists":"","*":"In silico medicine"},{"ns":0,"exists":"","*":"In vitro"},{"ns":0,"exists":"","*":"In vivo"},{"ns":0,"exists":"","*":"Intention to treat"},{"ns":0,"exists":"","*":"Medical device"},{"ns":0,"exists":"","*":"Medicinal product"},{"ns":0,"exists":"","*":"Pre-clinical development"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Statistic"},{"ns":0,"exists":"","*":"Virtual Physiological Human"}],"templates":[{"ns":10,"exists":"","*":"Template:CC-notice"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg","CC-BY-icon-80x15.png"],"externallinks":["http://www.vph-institute.org/upload/vphinst-position-on-fp8-greenpaper-v3_5192443874603.pdf","//doi.org/10.1038/nrd4090","//www.ncbi.nlm.nih.gov/pubmed/23903212","//doi.org/10.1038/clpt.2013.54","//doi.org/10.1038/psp.2013.6","//doi.org/10.1152/ajpheart.00808.2011","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3638492","//doi.org/10.1098/rsfs.2013.0004","//doi.org/10.1109/TBME.2013.2244600","//doi.org/10.1097/01.CCM.0000142394.28791.C3","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2681269","//doi.org/10.1177/193229680900300106","//www.ncbi.nlm.nih.gov/pubmed/19444330","http://avicenna-isct.org/wp-content/uploads/2015/05/Avicenna_roadmap_v3.pdf","//doi.org/10.1038/psp.2013.7","http://www.taverna.org.uk/introduction/what-is-in-silico-experimentation/"],"sections":[{"toclevel":1,"level":"2","line":"History","number":"1","index":"1","fromtitle":"In_silico_clinical_trials","byteoffset":510,"anchor":"History"},{"toclevel":1,"level":"2","line":"Rationale","number":"2","index":"2","fromtitle":"In_silico_clinical_trials","byteoffset":1002,"anchor":"Rationale"},{"toclevel":1,"level":"2","line":"Aim","number":"3","index":"3","fromtitle":"In_silico_clinical_trials","byteoffset":6567,"anchor":"Aim"},{"toclevel":1,"level":"2","line":"See also","number":"4","index":"4","fromtitle":"In_silico_clinical_trials","byteoffset":12767,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"5","index":"5","fromtitle":"In_silico_clinical_trials","byteoffset":12865,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"6","index":"6","fromtitle":"In_silico_clinical_trials","byteoffset":12999,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"<i>In silico</i> clinical trials","iwlinks":[{"prefix":"creativecommons","url":"https://creativecommons.org/licenses/by/4.0/","*":"creativecommons:by/4.0/"}],"properties":[{"name":"displaytitle","*":"<i>In silico</i> clinical trials"},{"name":"wikibase_item","*":"Q22909167"}]}}